Clinical assessment of Navauppu Mezhugu for Painful menstruation.

A Study on effectiveness of Nava Uppu Mezhugu for Aga Soothaga Vali (Primary Dysmenorrhoea)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/02/049786

Enrollment

Registered

2023-02-16

Start date

Unknown

Completion date

Unknown

Last updated

2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N946- Dysmenorrhea, unspecified

Interventions

Intervention1: NAVA UPPU MEZHUGU(INTERNAL): Dosage: 35-40 mg (Only in the morning) Adjuvant: Palm jaggery Duration :3 days of menstruation for 3 consecutive months Control Intervention1: Not Applicabl

Eligibility

Inclusion criteria

Inclusion criteria: Women in the age group between 11 to 25 years Onset of pain within 6-12 hours after the onset of menses Nulliparous women Cramping or pain in the lower abdomen Pelvic pain Low back pain Pain spreading down the legs. Patient willing to sign the informed consent.

Exclusion criteria

Exclusion criteria: Presence of any pelvic pathology such as chronic pelvic infection, pelvic endometriosis, adenomyosis, uterine fibroid and endometrial polyp Presence of any associated severe systemic illness Uterine or cervical polyp

Design outcomes

Primary

Measure	Time frame
Significance reduction in clinical symptom assessed by using WaLIDD score.Timepoint: 6 Months	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Megganah

National Institute of Siddha

gvennils@gmail.com9789093986

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026